Press releases
- Amneal Reports First Quarter 2024 Financial Results
- Amneal Announces U.S. FDA Approval of Over-the-Counter Naloxone Hydrochloride Nasal Spray for Emergency Treatment of an Opioid Overdose
- Amneal Launches PEMRYDI RTU®, the First Ready-to-Use Version of Important Oncology Injectable Medicine
- Amneal to Report First Quarter 2024 Results on May 3, 2024
- Amneal to Ring the Nasdaq Closing Bell on April 2, 2024
- Amneal Receives U.S. FDA Approval for Ciprofloxacin and Dexamethasone Otic Suspension
- Amneal Reports Fourth Quarter and Full Year 2023 Financial Results
- Amneal Enters into Exclusive European Licensing Agreement with Zambon Biotech for IPX203
More ▼
Key statistics
On Wednesday, Amneal Pharmaceuticals Inc (2DT:DUS) closed at 6.25, -1.57% below its 52-week high of 6.35, set on Mar 01, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 6.25 |
---|---|
High | 6.25 |
Low | 6.25 |
Bid | 6.15 |
Offer | 6.45 |
Previous close | 6.15 |
Average volume | 242.78 |
---|---|
Shares outstanding | 308.65m |
Free float | 124.19m |
P/E (TTM) | -- |
Market cap | 2.11bn USD |
EPS (TTM) | -0.5642 USD |
Data delayed at least 15 minutes, as of May 15 2024 18:30 BST.
More ▼